title: Cardioprotection with resveratrol pretreatment: improved beneficial effects over standard treatment in rat hearts after global ischemia.
abstract: OBJECTIVE
  The major objective of the present study is to evaluate the potential role of resveratrol (RVT), a natural antioxidant found in grapes and red wine, in protecting the myocardium from the deleterious effects of ischemia-reperfusion (I/R) injury using isolated rat hearts.
  
  
  METHODS
  Langendorff perfused isolated rat hearts were subjected to 60 min of global ischemia following 60 min of reperfusion. RVT was given according to chronic pretreatment and/or acute treatment protocols. Animals received RVT at the dose of 20 mg/kg via an intragastric tube for 14 days before the experiment and/or at the infusion concentration of 10 microM for 30 min before the onset of ischemia. The myocardial postischemic recovery was compared using hemodynamic data (peak systolic pressure, end diastolic pressure, and +dP/dtmax), coronary flow, biochemical parameters (LDH, CK-MB, cTnI, myoglobin) from coronary effluent, and oxidative stress markers (MDA, GSH, carbonyl) from heart tissue homogenates in each group.
  
  
  RESULTS
  RVT pretreatment and treatment protocols have provided increased preservation in myocardial recovery following global ischemia compared to a non-treated group. Furthermore, the ischemic damage of myocardium was significantly lower in chronic pretreated rats than in the acutely treated group. In contrast, no significant difference was observed in cardioprotective effects of RVT between the only pretreated group, and both the pretreated and treated group throughout reperfusion.
  
  
  CONCLUSIONS
  The findings from this study indicate that RVT has potent cardioprotective properties against I/R injury in rat hearts. The study also highlighted that the administration of RVT, as pretreatment, has amplified the beneficial effects over the standard treatment.
authors.affiliation: Department of Cardiovascular Surgery, Osmangazi University, Medical Faculty, Eskisehir, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Dernek
authors.forename: M
authors.initials: M
authors.lastname: Ikizler
authors.forename: N
authors.initials: N
authors.lastname: Erkasap
authors.forename: B
authors.initials: B
authors.lastname: Ergun
authors.forename: T
authors.initials: T
authors.lastname: Koken
authors.forename: K
authors.initials: K
authors.lastname: Yilmaz
authors.forename: B
authors.initials: B
authors.lastname: Sevin
authors.forename: Z
authors.initials: Z
authors.lastname: Kaygisiz
authors.forename: T
authors.initials: T
authors.lastname: Kural
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D006439:Hemodynamics / Q000502:physiology; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008297:Male; D017202:Myocardial Ischemia / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000009:adverse effects* / Q000379:methods; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D011336:Probability; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D012680:Sensitivity and Specificity; D013267:Stilbenes / Q000494:pharmacology*; D015996:Survival Rate
chemical_list: D013267:Stilbenes; D000077185:Resveratrol